

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GIL-AD et al.

Group Art Unit: 1623

Serial Number: 10/774,694

Conf. No.: 8587

Filed: February 10, 2004

Examiner: OLSON, Eric

For: ANTI-PROLIFERATIVE DRUGS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

[ ] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[ X ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

[ ] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or

[X] ii. a check in the amount required by 37 C.F.R. § 1.17(p).

[ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.

[ ] Certification report(e) below; and

[ ] a check in the amount as required by § 1.17(p).

[ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

[ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

01/18/2007 HMARZII 08000128 10774694

01 FC:1806

180.00 OP

[ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[ ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[ ] Appropriate certification is attached.

[ X ] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[ X ] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

And/or


[ X ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:  
or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**THE NATH LAW GROUP**

By:



Gary M. Nath  
Registration No. 26,965  
Susanne M. Hopkins  
Registration No. 33,247  
Customer No. 20529

Date: January 17, 2007  
THE NATH LAW GROUP  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/SMH/dd (IDS.revisedNov03)

FORM PTO-1449

## INFORMATION DISCLOSURE CITATION

Atty Docket  
25464XSerial No.  
10/774,694Applicant  
GIL-AD et al.Filing Date  
February 10, 2004Group Art Unit  
1623

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
ESO	AA	5,789,339	25 Aug 1998	Brandes			28 Jun 1993
ESO	AB	5,795,895	18 Aug 1998	Anchors			13 Jun 1997
ESO	AC	5,639,950	17 Jun 1997	Verma, et al.			29 Jun 1994
ESO	AD	4,018,985	19 Apr 1977	Molloy, et al.			17 Sep 1975
ESO	AE	4,314,081	2 Feb 1982	Molloy, et al.			10 Jan 1974
ESO	AF	5,110,802	5 May 1992	Cantin, et al.			14 Jul 1987
ESO	AG	5,166,437	24 Nov 1992	Kairisalo, et al.			23 Nov 1990
ESO	AH	5,194,428	16 Mar 1993	Agrawal, et al.			30 Apr 1990
ESO	AI	5,216,141	1 Jun 1993	Benner			6 Jun 1988
ESO	AJ	5,776,925	7 Jul 1998	Young, et al.			25 Jan 1996
ESO	AK	5,859,065	12 Jan 1999	Brandes			1 Aug 1997
ESO	AL	6,258,853	10 Jul 2001	Stowell, et al.			31 Jan 2001

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
ESO	AM	WO 94/18961 A1	1 Sep 1994	WIPO			N/A
ESO	AN	WO 92/11035 A1	9 Jul 1992	WIPO			N/A
ESO	AO	WO 02/43652 A2	6 Jun 2002	WIPO			N/A
ESO	AP	WO 99/24415 A1	20 May 1999	WIPO			abstract
ESO	AQ	WO 99/25344 A1	27 May 1999	WIPO			N/A

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ESO	AR	Abdul, M., et al., "Growth-Inhibitory Effects of Serotonin Uptake Inhibitors on Human Prostate Carcinoma Cell Lines", <u>The Journal of Urology</u> , Vol. 154, Pg. 247-250, (1995).
ESO	AS	Bachmeier, B. E., et al., "Human Keratinocyte Cell Lines Differ in the Expression of the Collagenolytic Matrix Metalloproteinases-1, -8, and -13 and of TIMP-1", <u>Biol. Chem.</u> Vol. 381, Pg. 509-516, (2000).
ESO	AT	Bradley, D. J., et al., "Elicitor- and Wound-Induced Oxidative Cross-Linking of a Proline-Rich Plant Cell Wall Protein: A Novel, Rapid Defense Response", <u>Cell</u> , Vol. 70, Pg. 21-30, (1992).

Examiner /Eric Olson/

Date Considered 02/23/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.

<b>PTO FORM-1449</b>		Inventor: GIL-AD, et al.		Art Unit: 1623	
<b>INFORMATION DISCLOSURE</b>		Appl. No.: 10/774,694		Examiner: unknown	
<b>CITATION</b>		Filing Date: February 10, 2004			
<b>U.S. PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
ESO	AU	6,024,977	15 Feb 2000	Yatvin, et al.	3 Sep 1997
	AV				
	AW				
	AX				
	AY				
	AZ				
	AAA				
	AAB				
	AAC				
	AAD				
	AAE				
	AAF				
<b>FOREIGN PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Public. Date	Country	Translation
ESO	AAG	681780 A5	28 May 1993	CH	NO
ESO	AAH	WO 01/80896 A2	1 Nov 2001	WIPO	N/A
ESO	AAI	WO 94/18961 A1	1 Sep 1994	WIPO	N/A
ESO	AAJ	2660194	4 Oct 1991	FR	NO
<b>OTHER</b>					
Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)				
ESO	AAK	Brandes, L. J., et al., "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", <u>Cancer Research</u> , Vol. 52, Pg. 3796-3800, (1992).			
ESO	AAL	Calabresi, P., et al., "Chemotherapy of Neoplastic Diseases", <u>The Pharmacological Basis of Therapeutics</u> , Section XII, Pg. 1202-1263, (1990).			
ESO	AAM	Cookson, J., et al., "Fluoxetine: therapeutic and undesirable effects", <u>Hospital Medicine</u> , Vol. 59, No. 8, Pg. 622-626, (1998).			
ESO	AAN	Cotterchio, M., et al., "Antidepressant Medication Use and Breast Cancer Risk", <u>American Journal of Epidemiology</u> , Vol. 151, No. 10, Pg. 951-957, (2000).			
ESO	AAO	Dalton, W. S., "Reversing Multidrug-Resistance in the Laboratory and Clinic", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 31, Pg. 520-521, (1990).			
ESO	AAP	DeVita, Jr., V. T., et al., "Cancer, Principles & Practice of Oncology, Vol. 2, 4 <sup>th</sup> Ed., Pg. 2661-2664, (1993).			
ESO	AAQ	Deutch, C. E., et al., "Post-transcriptional regulation of a salt-inducible alfalfa gene encoding a putative chimeric proline-rich cell wall protein", <u>Plant Molecular Biology</u> , Vol. 27, Pg. 411-418, (1995).			
ESO	AAR	Esaka, M., et al., "Specific Secretion of Proline-Rich Proteins by Salt-Adapted Winged Bean Cells", <u>Plant Cell Physiol.</u> , Vol. 36, No. 3, Pg. 441-446, (1995).			
ESO	AAS	Galil, S., et al., "Enhanced levels of free and protein-bound threonine in transgenic alfalfa ( <i>Medicago sativa</i> L.) expressing a bacterial feedback-insensitive aspartate kinase gene", <u>Transgenic Research</u> , Vol. 9, pp 137-144, (2000)			

ESO	AAT	Goodwin, W., et al., "Transcripts of a gene encoding a putative cell wall-plasma membrane linker protein are specifically cold-induced in <i>Brassica napus</i> ", <u>Plant Molecular Biology</u> , Vol. 31, Pg. 771-781, (1996).
ESO	AAU	Gupta, M. A., et al., "Psychotropic drugs in dermatology", <u>J Am Acad Dermatol</u> , Vol. 14, No. 4, Pg. 633-645, (April 1986).
ESO	AAV	Hare, P. D., et al., "Metabolic implications of stress-induced praline accumulation in plants", <u>Plant Growth Regulation</u> , Vol. 21, Pg. 79-102, (1997).
ESO	AAW	Hemlock, C., et al., "Fluoxetine-induced Psoriasis", <u>The Annals of Pharmacotherapy</u> , Vol. 26, Pg. 211-212, (February 1992).
ESO	AAx	Johnson, R. K., et al., "In Vivo Characteristics of Resistance and Cross-Resistance of an Adriamycin-Resistant Subline of P388 Leukemia", <u>Cancer Treatment Rep.</u> , Vol. 62, No. 10 Pg. 1535-1547, (1978).
ESO	AAy	Karchi, H., et al., "Lysine synthesis and catabolism are coordinately regulated during tobacco seed development", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, Pg. 2577-2581, (March 1994).
ESO	AAZ	Kaye, C., et al., "Characterization of a Gene for Spinach CAP160 and Expression of Two Spinach Cold-Acclimation Proteins in Tobacco", <u>Plant Physiol.</u> , Vol. 116, Pg. 1367-1377, (1998).
ESO	AAAA	Memelink, J., et al., "Structure and regulation of tobacco extensin", <u>The Plant Journal</u> , Vol. 4, No. 6, Pg. 1011-1022, (1993).
ESO	AAAB	Nanjo, T., et al., "Antisense suppression of praline degradation improves tolerance to freezing and salinity in <i>Arabidopsis thaliana</i> ", <u>FEBS Letters</u> , Vol. 461, Pg. 205-210, (1999).
ESO	AAAC	Nordenberg, J., et al., "Effects of Psychotropic Drugs on Cell Proliferation and Differentiation", <u>Biochemical Pharmacology</u> , Vol. 58, Pg. 1229-1236, (1999).
ESO	AAAD	Sonneveld, P., et al., "Inhibitors of multidrug resistance", <u>Curr. Opin. Oncol.</u> , Vol. 9, No. 6, Pg. 543-548, (1997).
ESO	AAAE	Strobl, J. S., et al., "The cell death response to $\gamma$ -radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide", <u>Breast Cancer Research and Treatment</u> , Vol. 51, Pg. 83-95, (1998).
ESO	AAAF	Szoke, A., et al., "Subcellular Location of $\Delta^1$ -Pyrroline-5-Carboxylate Reductase in Root/Nodule and Leaf of Soybean <sup>1</sup> ", <u>Plant Physiol.</u> , Vol. 99, Pg. 1642-1649, (1992).
ESO	AAAG	Tan, B., et al., "Multidrug resistance transporters and modulation", <u>Current Opinion in Oncology</u> , Vol. 12, Pg. 450-458, (2000).
ESO	AAAH	Tennyson, H., et al., "Neurotropic and Psychotropic Drugs in Dermatology", <u>Systemic Dermatologic Therapy</u> , Vol. 19, No. 1, Pg. 179-197, (January 2001).
ESO	AAAI	Vindeløv, L. L., et al., "A Detergent-Trypsin Method for the Preparation of Nuclei for Flow Cytometric DNA Analysis", <u>Cytometry</u> , Vol. 3, No. 5, Pg. 323-327, (1983).
ESO	AAAJ	Wang, P. S., et al., "Antidepressant use and the risk of breast cancer: A non-association", <u>Journal of Clinical Epidemiology</u> , Vol. 54, Pg. 728-734, (2001).
ESO	AAAK	Xia, Z., et al., "The Antidepressants Imipramine, Clomipramine, and Citalopram Induce Apoptosis in Human Acute Myeloid Leukemia HL-60 Cells via Caspase-3 Activation", <u>J Biochem Molecular Toxicology</u> , Vol. 13, No. 6, Pg. 338-347, (1999).

